Citizenship, medical expertise and the capitalist regulatory state in Europe

Sociology

Volumn 36, Issue 1, 2002, Pages 67-88

  Abraham, John ^a   Lewis, Graham ^b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Citizenship; Disorganized capitalism; Medical authority; Pharmaceutical industry; Regulatory state

Indexed keywords

EID: 0036464130     PISSN: 00380385     EISSN: None     Source Type: Journal    
DOI: 10.1177/0038038502036001004     Document Type: Article

References (105)

1. Bias in science and medical knowledge: The opren controversy
2. The production and reception of scientific papers in the academic-industrial complex: The clinical evaluation of a new medicine
3. The science and politics of medicines regulation
4. Democracy, technocracy and the secret state of medicines control: Expert and non-expert perspectives
5. The drug lag issue: The debate seen from an international perspective
6. New ABPI director stresses importance of two-way flow between medicines division and industry
7. Opren action committee sues UK CSM and licensing authority
8. Medical journalist is given access to documents in opren claim litigation
9. UK meds division - Proposed changes
10. Swedes want SLA changes
11. ABPI's "blueprint for Europe"
12. New UK licence fees proposed
13. UK revised licensing fee proposals
14. Swedish regulatory productivity
15. BGA and regulatory policy
16. UK MCA director named
17. BGA insists on intellectual input
18. UK licensing fees debated
19. UK MCA sets targets
20. BGA approvals in 1988
21. BGA must observe time limit
22. Approval times in Sweden
23. Swedish SLA becomes independent from July
24. Products rejected in Sweden in 1989/90
25. UK MCA director reports on progress
26. UK MCA meets licensing/financial targets
27. Failure to act case to cost DM 300,000
28. MCA stresses quality of management
29. UK medicines information bill launched
30. Swedish MPA changes its ways
31. UK medicines information bill clears first hurdle
32. UK DoH consults on medicines transparency
33. UK medicines information bill blocked
34. BGA figures clarify problems
35. 26 NCEs launched in Germany in 1993
36. 47 NCEs approved in Sweden in 1993
37. More changes at German agency
38. UK gives lawyers access to ADR data
39. UK MCA reviews its year
40. Glaxo's expanding galaxy
41. Strategy of risk-benefit analysis
42. Committee on review of medicines
43. The swedish medicines regulatory system - With some notes on the scandinavia situation
44. Regulatory laws and political culture in the US and Germany
45. New EC procedures for authorisation of medicinal products, (1)
46. Sad story of the happy pills
47. Halcion nights: A sociological account
48. New procedures affecting the conduct of clinical trials in the UK
49. Citizenship, universalism, migration and the risks of exclusion
50. Legal administrative culture as policy determinants: Licensing and the drug industry
51. Citizenship, consumption and rights
52. Medical autonomy and the UK state: 1975 to 2025
53. Guest interview - The role of the German BfArM within the new EC regulatory framework (1)
54. Opren
55. International drug regulation
56. Requirements in Sweden
57. International regulatory, review times converge
58. Ruling class strategies and citizenship
59. Citizenship and social class
60. Secrecy and medicines
61. Globalization, migration and the nation-state: The path to post-national Europe?
62. Sexuality and citizenship
63. Citizenship and modernity
64. Citizenship and exclusion: Reconstructing the European union
65. Political power beyond the state: Problematics of government
66. The drug regulatory system in the FRG
67. Trends in pharmaceutical innovation: The introduction of products on to the UK market, 1960-1989
68. Outline of a theory of citizenship
69. Mobile sociology
70. Is citizenship gendered?
71. Globalisation, corporate identity and european technology policy
72. BfArM letter to VFA